Looking at the positives: proactive management of STIs in people with HIV

Table 2 Potential DAA/ART drug interactions

DAA	ART	Change required
DCV	EFV	Increase DCV dose to 90 mg
DCV	NVP/ETR	Likely increase DCV dose to 90 mg (no data)
DCV	ATZ + EVG/COBI/FTC/TDF	Decrease DCV dose to 30 mg
LDV/SOF	TDF-based regimens	Use with caution, esp. if renal impairment
PROD	ART	Many drug interactions—do not use
ELB/GRZ	PIs	Contraindicated—do not use
ELB/GRZ	NNRTIs (except RLV)	Contraindicated—do not use
ELB/GRZ	EVG/COBI/FTC/TDF	Contraindicated—do not use
SOF/VEL	EFV	Contraindicated—do not use

Data source: HepC Drug Interactions (http://www.hep-druginteractions.org)
ATZ atazanavir, COBI cobicistat, DCV daclatasvir, ELB elbasvir, ETR etravirine, EFV efavirenz, EVG elvitegravir, FTC emtricitabine, GRZ grazoprevir, LDV ledipasvir, NNRTIs non-nuclease reverse-transcriptase inhibitors, NVP nevirapine, PIs protease inhibitors, PROD paritaprevir/ritonavir–ombitasvir and dasabuvir, RPV rilpivarine, SOF sofosbuvir, TDF tenofovir disoproxil fumarate

ISSN: 1742-6405